Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia

Bibliographic Details
Main Authors:	Karina J. Cancel-Artau, MD, Angélica C. Marrero-Pérez, MD, Eduardo A. Michelén-Gómez, MD, Xavier Sánchez-Flores, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	JAAD Case Reports
Subjects:	amivantamab endothelial growth factor receptor inhibitor ulcer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512624000250

Internet